Document Classification

Section Type: RESULTS

Text: After treatment, the level of plasma CD4 and CD4/CD8 ratio were significantly lower in group B than those in group A (P < 0. 05) ; the response rate (RR) was 32. 00 % (24/75) and 38. 67 % (29/75) in group B and A respectively, showing insignificant difference (P > 0. 05), and the clinical benefit rate (CBR) was 58. 67 % (44/75) in group A, lower than that in group B (85. 33 % (64/75), P < 0. 05) ; the quality of life (QOL) in group A was superior to that in group B (P < 0. 05) ; and the incidence of main adverse reaction to chemotherapeutic agents was significantly lower in group A as compared to that in group B (P < 0. 05).